Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL)
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20709668
DOI
10.3816/clml.2010.n.061
PII: S2152-2650(11)70037-4
Knihovny.cz E-resources
- MeSH
- Alemtuzumab MeSH
- Chlorambucil therapeutic use MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell diagnosis drug therapy epidemiology MeSH
- Adult MeSH
- Hematology MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Middle Aged MeSH
- Humans MeSH
- Disease Management MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Antibodies, Neoplasm therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Vidarabine analogs & derivatives therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Alemtuzumab MeSH
- Chlorambucil MeSH
- fludarabine MeSH Browser
- Antibodies, Monoclonal, Humanized MeSH
- Antibodies, Monoclonal MeSH
- Antibodies, Neoplasm MeSH
- Vidarabine MeSH
PURPOSE: Currently, pathogenesis, new prognostic factors, or new therapy in chronic lymphocytic leukemia (CLL) are frequently discussed; however, up-to-date data concerning the incidence and the management of CLL in everyday hematologic practice are still missing. The aim of our study was to find out the accurate epidemiologic situation of CLL and the diagnostic and therapeutic preferences of hematologists in the preselect area: the South Moravian Region (1,127,718 inhabitants, white race). PATIENTS AND METHODS: The total number of 540 patients (median age at the time of diagnosis, 65 years; sex, 306 men and 234 women) who had been followed in 2008 were included in the analysis. RESULTS: In the years 2006 and 2007, the incidence of CLL was 5.8 and 6.2, respectively, per 100,000; the prevalence was 48 per 100,000. Chronic lymphocytic leukemia treatment was indicated in 194 patients (36%); 93 (17%) of them also underwent the second line of treatment. Of these 194 patients, 64 patients (33%) were given fludarabine-based regimens, and 74 patients (38%) received chlorambucil as a first line of treatment. Thirty patients were treated within clinical trials. Although the treatment was indicated in only one third of patients (36%), new prognostic factors were examined in > 50% of patients. CONCLUSION: The ascertained incidence of CLL in our region is higher than declared incidence in the past. Evidently, CLL became an often misdiagnosed and underreported disease.
References provided by Crossref.org
Practical approach to management of chronic lymphocytic leukemia
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
